Safeguarding the World’s Blood Supply

Press Releases

2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
DateSubject
October, 31 2002 Cerus Corporation Receives Commitment for $50 Million Financing From Baxter
View Release
October, 31 2002 Cerus Corporation Announces Third Quarter Results
View Release
October, 24 2002 Webcast Alert: Cerus Corporation Announces Third Quarter Financial Results Conference Call
View Release
October, 23 2002 Cerus Corporation Appoints Elizabeth M. Tillson, Ph.D. as Vice President, Regulatory Affairs and Quality
View Release
October, 16 2002 Baxter and Cerus Announce Final European Regulatory Clearance for the First Pathogen Inactivation System for Platelets
View Release
September, 26 2002 Cerus Corporation Receives $6.5 Million Award in Expanded Collaboration With the U.S. Armed Forces
View Release
July, 31 2002 Cerus Corporation Announces Second Quarter Results
View Release
July, 17 2002 Cerus Corporation Invites You to Join a Webcast of Its Second Quarter Conference Call.
View Release
July, 11 2002 Cerus Corporation Receives $5 Million Milestone Payment From Baxter Healthcare Corporation
View Release
June, 26 2002 Cerus Corporation Expands U.S. Patent Coverage for Pathogen Inactivation in Blood
View Release
June, 04 2002 Cerus Invites You to a Company Update via the Web
View Release
June, 04 2002 Cerus and Baxter's INTERCEPT Disposable Set for Platelets Receives European Regulatory Approval.
View Release
April, 25 2002 Cerus Corporation Announces First Quarter Results
View Release
April, 12 2002 Cerus Corporation Invites You to Join a Webcast of its First Quarter Conference Call
View Release
April, 11 2002 Cerus Corporation Names William R. Rohn to Board of Directors
View Release
February, 21 2002 Cerus and Baxter Receive FDA Concurrence to Begin Phase III INTERCEPT Red Blood Cell Trial in Chronic Indications
View Release
January, 24 2002 Cerus Corporation Announces Fourth Quarter and Year End 2001 Results
View Release
January, 14 2002 Cerus Corporation Invites You to Join a Webcast of Its Fourth Quarter Conference Call
View Release
January, 09 2002 Cerus and Baxter Initiate Clinical Site in Pivotal Phase III Trial for INTERCEPT Red Blood Cell System
View Release

Links

    Global Headquarters

  • 2550 Stanwell Drive
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600

Email Alerts

Alerts are emailed to you when certain new company information is posted to this site.

Sign up for Email Alerts

Copyright (c) 2019 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc.